Abstract:Based on the structures of nine existing STAT3 phosphorylation inhibitors, a novel small‐molecule compound with a simple structure was constructed. Derivative 4D exhibited good biological activity in colorectal cancer cell lines, induced apoptosis of tumor cells, and showed good bioactivity in vitro and in vivo, exerting its biological activity by inhibiting STAT3 phosphorylation. 4D also significantly reduced the tumor tissue in mouse tumor models. The phosphorylation of STAT3 plays a critical physiological role in the proliferation of rectal cancer. Hence, inhibiting STAT3 phosphorylation is an effective anticancer approach. In this work, we designed a novel 5‐R'‐1‐naphthylmethylamide scaffold as a small molecule inhibitor of STAT3 phosphorylation. The results showed that 3D and 4D have exceptional inhibitory ability against three different colorectal cancer (CRC) cell lines, and can induce apoptosis of CRC cells by inhibiting STAT3 phosphorylation, while having no killing effect on normal human cells. 3D and 4D can inhibit STAT3 phosphorylation in a time‐ and concentration‐dependent manner, and also inhibit the nuclear translocation of interleukin (IL)‐6‐induced STAT3. In the in vivo tumor model research, 4D significantly reduced the tumor volume of mice and had no drug toxicity on other organ tissues. Furthermore, molecular docking studies revealed that 3D and 4D had greater binding free energy when interacting with the STAT3 SH2 structural domain, and could establish H–π interaction modes. Dynamic simulation studies indicated that both compounds were able to bind tightly to STAT3.

Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study

Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy

Discovery, Optimization, and Evaluation of Novel N -(Benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine Analogues as Potent STAT3 Inhibitors for Cancer Treatment

Discovery of potent STAT3 inhibitors using structure-based virtual screening, molecular dynamic simulation, and biological evaluation

Design, Synthesis and Biological Evaluation of Benzyloxyphenyl-Methylaminophenol Derivatives As STAT3 Signaling Pathway Inhibitors.

Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition

Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking

Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors

Design, synthesis, and biological evaluation of naphthoylamide derivatives as inhibitors of STAT3 phosphorylation

Identification and Characterization of Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway by Virtual Screening.

Identification of New Shikonin Derivatives As Antitumor Agents Targeting Stat3 Sh2 Domain

Design, Synthesis and Biological Evaluation of Small-Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (stat3) Signaling Pathway

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Identification of New Shikonin Derivatives As STAT3 Inhibitors.

4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway

Design, synthesis and biological evaluation of novel naphthoquinothiazole derivatives as potent antitumor agents through inhibiting STAT3

Discovery of 4-methoxy-N-(1-naphthyl)benzenesulfonamide derivatives as small molecule dual-target inhibitors of tubulin and signal transducer and activator of transcription 3 (STAT3) based on ABT-751

Benzobis(imidazole) derivatives as STAT3 signal inhibitors with antitumor activity

Discovery of Novel Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway by Virtual Screening

Discovering novel derivatives of STAT3 and HDAC inhibitors with anti-tumor activity

Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain